The Use of Ultrasound in Perimenopausal and Postmenopausal Bleeding

Steven R. Goldstein, MD
New York University School of Medicine

Disclosures

Steven R. Goldstein, MD

Relevant Financial Relationships:
- Goldstein Gyn Advisory Board: AbbVie, Azure Biotech, IBSA, JDS Therapeutics, Juniper Pharma, Pfizer, Radius, Sermonix, Therapeutics MD
- Equipment Loan: Philips
- Consultant: Cook OB/GYN, Cooper Surgical
- Equity held: Azure Biotech, Sermonix
- Speakers Bureau: JDS Therapeutics, Pfizer, Shionogi

Learning Objectives

After completing this presentation, the learner will be able to:
1. Understand ultrasound based triage for women with abnormal uterine bleeding
2. Understand the shortcomings of blind endometrial sampling
3. Appreciate the indications for saline infusion sonohysterography (SIS)
4. Optimize their technique of saline infusion sonohysterography (SIS)

Lecture Outline

1. Endometrial normal and abnormal anatomy and pathophysiology:
   - Functionalis and basalis
   - Proliferative endometrium
   - Secretory endometrium
   - Postmenopausal endometrium
   - Atrophic endometrium
2. Definitions and demographics of bleeding
   - Perimenopausal vs. postmenopausal
   - Anatomic causes (polyps, myomas, hyperplasia, carcinoma)
   - Non-anatomic causes (DUB atrophy)
3. Role of transvaginal ultrasound
   - Negative predictive value of a thin distinct echo
   - Supporting data
   - Irregularities of endometrial surface
   - Ultrasound based triage of abnormal bleeding
4. Role of saline infusion sonohysterography (SIS)
   - Technique
   - Limitations of blind biopsy
5. Ultrasound limitations
   - Adenomyosis
   - Coexisting myoma
   - Axial uterus
   - Marked obesity
   - Previous surgery
6. Tips for enhanced success of SIS
   - Timing of procedure
   - Inability to thread catheter
   - Avoid performing during active bleeding
   - Avoid placing air into endometrial cavity
7. Latest recommendations from ACOG
   - Role of biopsy and its limitations
   - Role of transvaginal ultrasound, sonohysterography, office hysteroscopy
   - Change in the standard of care
Successful use of ultrasound in patients with bleeding begins with a short lesson in pathophysiology.

Ultrasound findings will simply reflect what is present (or not) anatomically.

What are normal or expected findings?

This will depend on what hormones are present and when they are present (or absent).

- THE ENDOMETRIUM CONSISTS OF A BASALIS AND A FUNCTIONALIS
- ESTROGEN CAUSES THE FUNCTIONALIS TO PROLIFERATE

PROLIFERATIVE EM

- Mitoses
- Note AMOUNT (or HEIGHT) of tissue
- **PROGESTERONE (OR IN SEQUENTIAL HORMONE THERAPY THE USE OF A PROGESTIN) WILL CONVERT AN ESTROGEN PRIMED ENDOMETRIAL FUNCTIONALIS TO A SECRETORY PHASE**

**SECRETORY EM**

- Glands line up in a linear fashion
- This results in a fiercely echogenic appearance on U/S

- **AFTER SHEDDING OF THE FUNCTIONALIS THE BASAL ENDOMETRIUM THAT REMAINS IS INITIALLY QUITE THIN AND WILL APPEAR AS SUCH ON TV U/S**
• **IN MENOPAUSE THERE IS NO ESTROGENIC STIMULATION OF THE FUNCTIONALIS AND THE ENDOMETRIUM IS ATROPHIC**

**ATROPHIC EM**

- Simple tubular glands
- Lacks mitotic activity
- Fibrotic stroma with increased collagen fibers
Since there is no "normal" width of endometrial thickness...

What is the proper use of the endometrial echo clinically?

Answer

The high negative predictive value of a thin distinct echo in patients with bleeding

Postmenopausal Bleeding Not So Easily Defined

- Menopause “The Final Menstrual Period”
- Retrospective diagnosis
- Classic definition: “No bleeding for 12 months due to a depletion of ovarian follicles”
- Serum measurements of FSH and estradiol notoriously unreliable – snapshot of ovarian function at that time.

Clinical Reality

- Erratic function of the ovaries in late perimenopause often makes it difficult to label bleeding as definitively postmenopausal
- Postmenopausal bleeding is “endometrial cancer until proven otherwise” Mandates evaluation
- ACOG Practice Bulletin July 2012 mandates that endometrial assessment to exclude cancer is indicated in any woman older than 40 years who is suspected of having abnormal uterine bleeding
Demographics of bleeding

• 1/3 of all visits to the gynecologist are for AUB
• 70% of Gyn consults in the peri and postmenopausal years are for bleeding

1. ACOG Practice Bulletin #128, July 2012

Demographics of bleeding (cont’d)

• Of perimenopausal women with AUB, roughly 80% will have no EM pathology (dysfunctional, anovulatory)
• Of postmenopausal women with bleeding (PMB) 3-7% will have EM cancer (range 1-14%). The majority of PMB is secondary to atrophy


Great Divide

• Anatomic pathology (polyps, myomas, hyperplasia, carcinoma)
• Absence of anatomic pathology (dysfunctional anovulatory in premenopause, atrophy in post menopause)

Ultrasound cannot make a histologic diagnosis

• Greatest contribution:
  • High negative predictive value in a thin distinct echo in excluding cancer
  • Ability of saline infusion enhancement to distinguish global vs. focal process

What is the data?

In the early 1990’s, TV U/S was utilized in women with postmenopausal bleeding to see if it could predict which patients lacked significant tissue and could avoid D&C or endometrial biopsy and its discomfort, expense, and risk.

Consistently, the finding of a thin distinct endometrial echo ≤ 4 to 5mm was shown to effectively exclude significant tissue in postmenopausal women with bleeding.

A series of large prospective studies from Western Europe were collected on postmenopausal women with bleeding.

For EM ≤ 4mm incidence of malignancy 1 in 917.

ACOG Committee Opinion (2/09) “When transvaginal ultrasound is performed for patients with postmenopausal bleeding and an EM thickness ≤ 4mm is found EM sampling is not required.”
WHAT IS THIS BASED ON...?

IS ENDOMETRIAL BIOPSY STILL NECESSARY? (con’t)

- False negative rate of TV U/S ≤ 4mm significantly less than a negative suction piston biopsy
- EM biopsy on patients with EM < 5mm: only 82% successfully performed, and of those only 27% gave a sample adequate for diagnosis

Elsadabesee, D. J Obstet Gynecol, 2005

In premenopausal women in whom the EM undergoes cyclical change, timing is crucial.

As the EM proliferates, it is not always topographically homogenous secondary to previous deliveries, D & C’s, Cesareans, myomectomies, etc.

Author Last Names
An algorithm of transvaginal ultrasound and saline infusion enhancement was proposed and tested prospectively.


**MATERIALS AND METHODS**

- 433 patients
- Perimenopausal (average age 47.4, range 37-54 years)
- Abnormal uterine bleeding (menorrhagia, metrorrhagia, or both)

**ABNORMAL PERIMENOPAUSAL BLEEDING:**

433 PATIENTS
Unenhanced Vaginal Ultrasound
280 patients ≤ 5mm (day 4-6)
153 patients > 5mm or nonvisualization of EM

**SALINE INFUSION SONOHYSTEROGRAPHY**

153 patients
44 (29%) for nonvisualization of EM
109 (71%) for EM > 5mm
RESULTS: OF 433 PATIENTS...

- 342 (78.9%) had dysfunctional bleeding
- 23 (5.3%) had submucous myomas
- 58 (13.4%) had polyps of which 3 were endocervical
- 15 (3.5%) had hyperplasia (of which 5 were symmetrical, 4 were focal, and 6 were in polyps
RESULTS: 15 PATIENTS HAD HYPERPLASIAS, OF WHICH...

- 5 were symmetrically thick (4 simple, 1 complex)
- 4 were focally thick (1 simple, 3 complex)
- 6 were in polyps (3 simple, 3 complex)

Blind EM biopsy (Pipelle) could have missed up to 79”non-global” lesions (18%) in patients with polyps, submucous myomas, focal hyperplasia.

SO WHY IS THERE AN ISSUE WITH BLIND BIOPSY (e.g.PIPELLE)?

PIPELLE AND EM CARCINOMA

Stovall (1991)
- 40 women with known carcinoma
- Pipelle prior to TAH
- Cancer diagnosed in 39/40 patients
- “Accuracy” = 97.5%
- Widely publicized

PIPELLE

- Rodriguez (1993) did prehysterectomy sampling with both Pipelle and Vabra. Pipelle sampled an average of 4% of EM lining (range 0-12%) vs. 41% for Vabra
- Pipelle agreed with post hysterectomy diagnosis in only 84% of cases

GUIDO R. ET AL (J REPROD MED, 1995)

65 pts with known carcinoma of EM
Pipelle under anesthesia prior to TAH
- missed 11/65 (16%) of cancers, of which
  3 were < 5% EM area
  4 were 6-25% EM area
  4 were 26-50% EM area
- 5/11 had tumor in polyps that were missed
  -- none that were >50% of surface area were missed

Authors concluded “Pipelle is excellent for detecting global processes in the endometrium.”
FALSE NEGATIVE RATE OF PIPELLE IN PATIENTS WITH KNOWN CARCINOMA (OTHER STUDIES)

- 7% (missed 2/26)
- 17% (missed 14/80)
- 33% (missed 12/37)
- Not nearly as reliable as the original work by Stovall

This study using U/S based triage in perimenopausal women resulted in...

- 65% to have an ultrasound exam only
- 17% to have only ultrasound and SIS
- 2.3% to have U/S, SIS and then pipelle bx
- 15.9% to have U/S, SIS D&C hysteroscopy for proven anatomic pathology

Ultrasound cannot give a tissue diagnosis...

The value of U/S and Sonohysterography is to TRIAGE patients to...
- NO anatomic pathology
- GLOBAL EM process (blind biopsy)
- FOCAL process (direct vision)

Crucial Caveat

- Not all uteri lend themselves to a meaningful ultrasound evaluation of endometrial thickness:
  - Adenomyosis
  - Coexisting myomas
  - Axial uterus
  - Marked obesity
  - Previous surgery
Recall the perimenopausal bleeding study…Use of SIS

- 153 patients had SIS out of 433 pts
- 44 (29%) for nonvisualization of EM
- 109 (71%) for EM > 5mm

THUS 44/433 (10.2%) OF PERIMENOPAUSAL WOMEN WITH AUB HAD AN EM ECHO THAT WAS NOT ADEQUATE TO BE USED DIAGONSTICALLY WITHOUT SALINE INFUSION

In such cases, SIS will enhance the transvaginal ultrasound.

Sonohysterography should be thought of as a subset of TV U/S when:

1) EM echo is not thin
1) EM echo is not well visualized

SONOHYSTEROGRAM

- FLUID INSTILLATION TO ENHANCE U/S DETAIL OF THE ENDOMETRIUM
- BECAUSE FLUID ENHANCES SOUND TRANSMISSION THESE WILL BE AMONG EASIEST U/S EXAMS TO INTERPRET
SONOHYSTEROGRAM: TECHNIQUE

- Pelvic scan, unenhanced (baseline appearance)
- Palpatory bimanual (anteverted, retroverted)
- Insert speculum
- Cleanse cervix
- Thread catheter (flush air first)

Goldstein

SONOHYSTEROGRAM: TECHNIQUE

- Remove speculum (carefully)
- Insert vaginal probe
- Instill sterile saline (10cc syringe), slowly, watch the screen
- Scan from cornua to cornua
- “reload”, turn 90° and scan from fundus to cervix
- Consider 3D scan ,if available

Goldstein

Tips to fine tune success for sonohysterography

Importance of 3D reconstruction

Realize that any single frozen ultrasound image is a two dimensional “snapshot” e.g. a single long axis view of a seemingly normal endometrium does not rule out pathology. The entire structure must be observed and three dimensional anatomy reconstructed.

Goldstein

Inability to thread the catheter

- Change position of speculum
- Use a “cervical stabilizer” (a fine toothed tenaculum)
- Small dilator (#13 Pratt) as last resort.

Goldstein
INADEQUATE DISTENSION OF THE CAVITY

- Requires very little fluid to outline cavity
- Same problem in hysteroscopy (some cavities are more difficult to distend)
- Check position of catheter

IMPORTANT CAVEAT

- Procedure is VERY time sensitive. It must be done on the last days of staining or the first days after the bleeding cycle ends when the endometrium will be as thin and uniform as possible
- As endometrium proliferates and thickens it is not always perfectly symmetrical (BEWARE Endometrial heterogeneity)
IN FACT…

...If the patient is bleeding so much or so often and cannot really tell what is a menses…

Consider an empiric course of a progestin “medical curetage” and then time the sonographic evaluation to the withdrawal bleed

AVOID GETTING AIR INTO THE CATHETER OR THE SYRINGE (AIR IS VERY ECHOGENIC !!)
Goldstein

SO BACK TO THE ACOG PRACTICE BULLETIN OF JULY 2012…

“The primary imaging test of the uterus for the evaluation of AUB is transvaginal ultrasonography.”

Goldstein

“An office endometrial biopsy is the first-line procedure of tissue sampling in the evaluation of patients with AUB.”

Goldstein

“If transvaginal ultrasonographic images are not adequate or further evaluation of the cavity is necessary, then sonohysterography (also called saline infusion sonohysterography) or hysteroscopy (preferably in the office setting is recommended).”

Goldstein
“Endometrial biopsy has high overall accuracy in diagnosing endometrial cancer when an adequate specimen is obtained and when the endometrial process is global.”

“If the cancer occupies less than 50% of the surface area of the endometrial cavity, the cancer can be missed by a blind endometrial biopsy sample.”

**THIS IS BASED ON THE DATA FROM GUIDO (1995)**

65 pts with known carcinoma of EM
Pipelle under anesthesia prior to TAH
- missed 11/65 (16%) of cancers, of which
  3 were < 5% EM area
  4 were 6-25% EM area
  4 were 26-50% EM area
- 5/11 had tumor in polyps that were missed
  -- all cancers>50% of surface area were found

Authors concluded “Pipelle is excellent for detecting global processes in the endometrium”

“A positive test result is more accurate for ruling in disease than a negative test result is for ruling it out.”

“These tests are only an endpoint when they reveal cancer or atypical complex hyperplasia.”

**NOW THE STANDARD OF CARE CORROBORATES THAT A NEGATIVE BLIND BIOPSY IS NOT A STOPPING POINT. CLINICIANS CAN STILL BEGIN WITH A BX BUT UNLESS IT IS MALIGNANT (OR COMPLEX ATYPICAL HYPERPLASIA) THE ENDOMETRIAL EVALUATION IS NOT COMPLETE!**
Conclusions

1. Understanding causes of bleeding in peri- and postmenopausal women allows better understanding of how to use transvaginal ultrasound.

2. There is a great divide between anatomic vs. no anatomic pathology.

3. A thin distinct EM echo will exclude significant anatomic pathology.

4. Sonohysterography (SIS) is a subset of transvaginal ultrasound when the EM echo is either not thin or not well visualized.

5. Transvaginal ultrasound and sonohysterography will be time sensitive in patients whose EM is cycling (and should be performed just as the bleeding cycle ends).

6. Transvaginal ultrasound is the first step in triage of AUB and PMB and when done properly will reduce any further invasive procedures in the majority of patients.
Key References


The role of transvaginal ultrasonography in the evaluation of postmenopausal bleeding. ACOG Committee Opinion 440, August 2009, Reaffirmed 2015


Sonohysterography, ACOG Technology Assessment 8, June 2012, Reaffirmed 2014